Opinion|Videos|December 4, 2024
Standard Treatment Options for BCG-Unresponsive NMIBC
Author(s)Katie S. Murray, DO, MS
Key Takeaways
- Intravesical chemotherapy aims to reduce recurrence and progression but may have limited efficacy and potential side effects.
- PD-L1 inhibitors enhance immune response but can cause immune-related adverse events and have variable patient response.
Katie S. Murray, DO, reviews the standard treatment options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), including intravesical chemotherapy, PD-L1 inhibitors, and other immunotherapeutic agents while highlighting the limitations of these therapies, such as incomplete response rates and potential adverse effects.
Advertisement
Episodes in this series
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What limitations do these options have?
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5